Vanda Pharmaceuticals (VNDA) Gross Profit (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 14 years of Gross Profit data on file, last reported at $48.6 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 4.38% year-over-year to $48.6 million; the trailing twelve-month figure through Mar 2026 stood at $205.1 million (up 7.97% YoY), and the FY2025 full-year result was $203.1 million, up 8.32% from the prior year.
• Gross Profit retreated to $48.6 million in Q1 2026, from $53.4 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $59.0 million in Q3 2022 to a low of $35.8 million in Q3 2023.
• A 5-year average of $49.8 million and a median of $49.9 million in 2025 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit sank 39.4% in 2023 and increased 26.15% in 2024, its largest moves.
• Tracing VNDA's Gross Profit over 5 years: stood at $58.2 million in 2022, then decreased by 28.21% to $41.8 million in 2023, then increased by 21.01% to $50.6 million in 2024, then rose by 5.51% to $53.4 million in 2025, then declined by 9.04% to $48.6 million in 2026.
• Business Quant data shows VNDA's Gross Profit at $48.6 million in Q1 2026, $53.4 million in Q4 2025, and $53.3 million in Q3 2025.